HGF
EmergingHGF/MET pathway activation is a key mechanism of resistance to EGFR-targeted lung cancer therapy.
HGF signals through a receptor called MET, and this pathway becoming overactive is a key reason some lung cancers stop responding to certain targeted drugs. Newer drugs specifically targeting this pathway are in active development.
Hepatocyte growth factor (HGF) is the ligand for the MET receptor tyrosine kinase, involved in cell growth, motility, and tissue regeneration, with significant relevance to cancer biology.
HGF/MET pathway activation is implicated in resistance to targeted therapies, particularly EGFR inhibitors in lung cancer, where MET amplification is a well-documented resistance mechanism.
HGF and MET pathway activity are assessed via tumor tissue testing (MET amplification/mutation testing) in treatment-resistance workups, particularly for lung cancer patients progressing on EGFR-targeted therapy.
MET inhibitors and HGF-targeted antibodies are active areas of drug development for MET-altered cancers and for overcoming EGFR-inhibitor resistance, representing a genuinely evolving area of precision oncology.
An active precision oncology drug development target for overcoming treatment resistance.
- General oncology reference literature on HGF/MET pathway in EGFR-inhibitor resistance in lung cancer.